Journal of Hepatology ’s Post

Dear Colleagues, A recent article in the American Journal of Case Reports by authors from Prince of Songkla University, Thailand, describes a case of advanced-stage hepatocellular carcinoma with rare orbital metastasis. Highlighting the importance of recognizing orbital metastasis as an initial HCC sign, the patient was treated successfully using dual immunotherapy (durvalumab - tremelimumab) combined with radiotherapy, showing significant clinical improvement and decreased alpha-fetoprotein levels. This underscores dual immunotherapy's potential in treating advanced HCC with orbital metastasis and need for early diagnostic investigations in at-risk patients. The complete report is available on the American Journal of Case Reports webpage. | https://lnkd.in/d5bxvkxe

Transarterial chemoembolization plus sorafenib as postop adjuvant therapy in patients with hepatocellular carcinoma with portal vein tumor thrombus resulted in longer recurrence-free survival & overall survival than sorafenib alone. https://ja.ma/3VPibMB

Dear Colleagues, A recent article in the American Journal of Case Reports by authors from Prince of Songkla University, Thailand, describes a case of advanced-stage hepatocellular carcinoma with rare orbital metastasis. Highlighting the importance of recognizing orbital metastasis as an initial HCC sign, the patient was treated successfully using dual immunotherapy (durvalumab - tremelimumab) combined with radiotherapy, showing significant clinical improvement and decreased alpha-fetoprotein levels. This underscores dual immunotherapy's potential in treating advanced HCC with orbital metastasis and need for early diagnostic investigations in at-risk patients. The complete report is available on the American Journal of Case Reports webpage. | https://lnkd.in/d6Dv-ZhT

Enfortumab vedotin better maintains health-related quality of life (HRQoL) compared with chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma. https://brnw.ch/21wHPY3 #blcsm

#cancerimmunotherapy for early-stage #NSCLC: when, what and to whom? ◾ The integration of cancer immunotherapy in managing early-stage NSCLC has shown promising results, backed by numerous positive clinical trials in recent years. ◾ Several #treatmentstrategies can be employed for patients with resectable NSCLC: #neoadjuvant, #adjuvant, and #perioperative treatments. However, the absence of direct comparative studies among these strategies makes it difficult to determine the added benefits of one over the others. ◾ Although neoadjuvant treatment offers several hypothetical advantages, such as reducing #tumorsize and inducing a sustained antitumor #immuneresponse, it also carries potential risks like precluding #surgery due to disease #progression or #toxicity. Conversely, post-operative treatment disposition is usually lower and patients might miss out on adjuvant therapy that could improve their #prognosis. ◾ Therefore, selecting a particular strategy depends on various factors, including #patient and #tumor characteristics, #patientpreferences, institutional #experience, local drug #reimbursement policies, and the availability of approved ICI-based regimens. The #multidisciplinarytumorboard plays a pivotal role in this decision-making process. 🔗 https://lnkd.in/eNpFhVbB

Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort https://lnkd.in/dxX-P__H

Recurrent/Disseminated Choroid Plexus Carcinoma: Overall Survival of > 23.6 Years in a One-Year and Nine-Month-Old Female Treated with Antineoplastons. Authors: Stanislaw R. Burzynski*, Gregory S. Burzynski, Tomasz Janicki and Samuel Beenken *Corresponding Author: Stanislaw R. Burzynski, MD, PhD, Director, Burzynski Clinic; 9432 Katy Freeway, Houston, Texas, USA. Abstract: Choroid plexus neoplasms (CPNs) are uncommon and have three types: papilloma, atypical papilloma, and carcinoma (CPC). There is no established treatment for recurrent/disseminated CPC. Objectives: CPN patients received treatment at the Burzynski Clinic https://lnkd.in/gehzMxmh

Waiting for #ECIO2024 Ablation Prediction and Confirmation for liver metastases from colorectal carcinoma (CRC) using XperGuide Software (Philips). 81 years old patient affected by two CRC metastases detected during MR follow-up. After catheterization of the hepatic artery, Dual-Phase CBCT was performed to detect the lesions and segmented using a dedicated software (XperGuide, Philips). After US-guided MW antenna (Emprint, Medtronic) placement in each lesion, a new CBCT was performed and superimposed to the first one to assess correct placement and evaluate the best ablation protocol to cover lesions and margins thanks to Ablation Prediction software.  After ablation, a new Dual-Phase CBCT was performed, and volume of the ablations segmented and superimposed with the segmented lesions. Residual tumor was detected and treated with an additional ablation. Final Dual-Phase CBCT and segmentation showed complete coverage of the segmented lesion within the ablation volume. European Conference on Interventional Oncology pushing boundaries of Interventional Oncology. #InterventionalOncology #IO #InterventionalRadiology #IR #ablation #navigation #verification #confirmation #liver #mets #LodIR Antonio Pio Francioso Maurizio Papa ASST Lodi - Azienda Socio Sanitaria Territoriale di Lodi

New Treatment For Advanced High-Grade Neuroendocrine Gastroenteropancreatic Tumors Find out the new FDA-approved treatment that is showing excellent results for patients. Watch this video to learn👇 ✅What are gastroenteropancreatic neuroendocrine tumors? ✅Why these tumors are often difficult to treat ✅What are somatostatin receptors (SSTR) ✅Differences between SSTRs and why this matters ✅What is the new FDA-approved drug for this? ✅How this new treatment works ✅The importance of the recent NETTER-2 Study ✅Exploring the results of the NETTER-2 Study ✅Next steps patients can take to find out if this treatment can help them Precision Oncology specialist, Alex Rolland, discusses a new leading-edge FDA-approved treatment that is a game-changer for patients with advanced high-grade gastroenteropancreatic neuroendocrine tumors. He explains the results of the recent NETTER-2 Study and the key takeaways that impact patients with this amazing new first-line treatment. He is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share the key takeaways that all cancer patients need to know about this new treatment – including next steps you can take to find out if it will work for you and how to access it. Click to watch 👉https://buff.ly/4aLHl35 👀 #HopeIsHere #PrecisionCancerMedicine